March 10, 2010 On June 30, 2010, brand-name atypical and typical antipsychotic medications to treat mental illness, anticonvulsant medications, and anti-diabetic medications will be added to Nevada's Medicaid preferred drug list (PDL). People taking these medications will have continued access; No prior authorization will be required if the patient maintains continuous Medicaid eligibility and continues to take the medication. After June 30, 2010, prior authorization for new clinical uses will be required. New patients must demonstrate therapeutic failure on one preferred atypical or typical antipsychotic, anticonvulsant, and anti-diabetic medication, before use of a non- preferred medication . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Nevada Medicaid Operations Transmittal Letter About Implementation of Preferred Drug List

March 10, 2010 On June 30, 2010, brand-name atypical and typical antipsychotic medications to treat mental illness, anticonvulsant medications, and anti-diabetic medications will be added to Nevada's Medicaid preferred drug list (PDL). People taking these medications will have continued access; No prior authorization will be required if the patient maintains continuous Medicaid eligibility and continues to take the medication. After June 30, 2010, prior authorization for new clinical uses will be required. New patients must demonstrate therapeutic failure on one preferred atypical or typical antipsychotic, anticonvulsant, and anti-diabetic medication, before use of a non- preferred medication . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.